So, were any of the 40 consenting nonseminoma high-risk stage I patients harmed by exposure to one modified-BEP cycle?
No, long-term data do not indicate relevant long-term toxicities. This is in concordance with other studies, which reported most serum parameters as well as lung function, audiometry, sexual function, and fertility rates as unaffected by adjuvant treatment with one to two cycles of BEP [7] [8] [9] . A Philadelphiapositive acute lymphoblastic leukemia occurred in one patient after additional three cycles of BEP for subsequent metastatic contralateral testicular cancer. This type of leukemia is not known to be related to chemotherapy, as opposed to the etoposide-induced acute myeloblastic leukemia with 11q23 abnormalities. This complication usually occurs after high cumulative etoposide doses exceeding 2000 mg/m 2 [10] . The study by Vidal is far from perfect: only 40 patients were finally eligible, the BEP dosing was experimental and the one arm design does not allow a comparison between outcomes following different management options. Further, embryonal carcinoma >50% is not a standard risk factor and apparently challenging for pathologists since 3 of the initial 44 patients (6.8%) had to be excluded from this study since the proportion of embryonal carcinoma was below 50% at re-evaluation. Lymphovascular invasion (LVI) is the most widely accepted risk factor for relapse and its presence is associated with a relapse rate of 50% compared with 15% in patients without LVI [11] [12] [13] . The experimental BEP schedule using a daily dose of 20 mg/m 2 of bleomycin, 120 mg/m 2 of etoposide, and 40 mg/m 2 of cisplatin administered i.v. on days 1-3 has no clear benefit over standard BEP, which remains the recommended regimen [14] .
Only 1 of 40 patients (2.5%) experienced recurrent TC. Without active treatment, i.e. surveillance, one would expect about 20 recurrences (50%). The relapsing patient received three salvage BEP courses for pulmonary metastases and died of a pulmonary distress syndrome within 4 weeks. This is a rare complication of metastatic TC patients within the good-risk group according IGCCCG and there is no indication that the previous adjuvant BEP contributed to this outcome [15] . Subsequent salvage chemotherapy is generally well tolerated and of similar efficacy as in patients during active surveillance. Of note, autopsy of the deceased patient showed no signs of active tumor.
In total, three patients (7.5%) developed a contralateral TC and the indicated lack of prevention of subsequent progression of carcinoma in situ has recently been reported by SWENOTECA [16] . Two additional patients required treatment of colorectal cancer which is unrelated to TC or its treatment, as opposed to cancers of the kidneys, thyroid or abdominal soft tissue [17] .
In conclusion, BEP ×1 is a well-tolerated means to abolish micrometastases and should be considered the standard treatment when adjuvant chemotherapy is to be given. Patients should be encouraged to consider their individual risk of recurrence on surveillance and all the consequences of this, both medical and socioeconomic, against the short-term toxicities of adjuvant chemotherapy. Only then can they make a balanced, informed choice. Physicians failing to present risk-adapted treatment strategies may harm their patients by infringing their autonomy and exposing them to a high risk of requiring salvage chemotherapy and possibly retroperitoneal lymph node dissection, with well-established long-term toxicities [18] .
